Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how AI is being used and ...
Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate ...
Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...
UnitedHealth Group appoints Dr. Scott Gottlieb to its board, enhancing leadership amongst a time in which the company looks ...
In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...
The FDA’s new Commissioner’s National Priority Voucher signals a transformative shift in U.S. drug review, tying accelerated approval to manufacturing readiness, domestic supply-chain strength, and ...
Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to ...
Artificial intelligence is a wildcard in the selection process, most profoundly in its agentic form. AI agents 2 will help ...
PE: How do global pharma growth strategies differ from domestic strategies? Ackerman: There are two different models for ...
Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their ...
FDA Commissioner Marty Makary announced FDA’s plans for a new drug approval pathway named the Plausible Mechanism Pathway ...
Stanton’s research, including the 2023 HBS case “Generative AI and the Future of Work,” underscores a pivotal truth: AI will not eliminate jobs en masse in the near term, but it will reshape them, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback